Fact-checked by Grok 2 weeks ago

Psychedelia


Psychedelia refers to the mid-20th-century cultural and aesthetic movement inspired by the perceptual distortions and expanded consciousness induced by hallucinogenic substances such as and mushrooms, encompassing vibrant, surreal , music, and countercultural philosophies challenging conventional social norms. The term "psychedelic," derived from Greek roots meaning "mind-manifesting," was coined in 1957 by to characterize the subjective effects of these compounds on , , and . Emerging prominently in the amid the , psychedelia influenced festivals, , and , with proponents viewing drug-induced states as pathways to and societal transformation, though links such experiences to both transient creative enhancements and risks of acute psychological distress. Defining characteristics include swirling, multicolored patterns in art and music featuring extended improvisations and distorted sounds, as exemplified by bands like The and visual works evoking . Controversies arose from recreational excesses, including reports of enduring negative psychological sequelae like , which fueled regulatory crackdowns and halted early therapeutic research despite initial promise in treating and anxiety. While recent peer-reviewed studies highlight potential benefits, historical analyses underscore how unsubstantiated advocacy and cultural backlash undermined credibility, prioritizing causal evidence of harms over anecdotal enthusiasm.

Etymology and Conceptual Foundations

Etymology

The term "psychedelic" was coined in 1956 by British in a letter to author , who had urged him to devise a neutral descriptor for substances inducing profound perceptual changes, distinct from the pathologizing implications of existing . Osmond derived it from roots psychē (ψυχή), meaning "mind" or "soul," and dēloûn (δηλοῦν), meaning "to make manifest" or "reveal," yielding a sense of "mind-manifesting" to capture observed pharmacological effects on without invoking supernatural or illusory elements. This neologism marked a deliberate shift from prior terms like "psychotomimetic," which connoted mimicry of psychotic states, or "hallucinogen," implying deceptive sensory distortions rather than heightened perceptual acuity grounded in empirical alterations of brain function. Osmond's choice reflected early clinical observations prioritizing verifiable changes in cognition and sensation over models equating such states to mental illness, aiming for a descriptor amenable to scientific inquiry into therapeutic potentials. By the mid-1960s, "psychedelic" extended adjectivally to of these perceptual models, evolving into the noun "psychedelia" to denote the emergent aesthetic and stylistic milieu in domains like visual design and sonic patterns, as evidenced in contemporaneous artistic outputs such as posters employing distorted and vibrant motifs. This linguistic adaptation retained the term's empirical anchoring in pharmacological phenomenology, framing the associated phenomena as extensions of mind-manifestation rather than esoteric mysticism.

Definition and Scope

Psychedelia refers to a perceptual, aesthetic, and subcultural phenomenon centered on evoking or representing of characterized by sensory distortions, , and non-ordinary perceptual processing, primarily through causal mechanisms tied to psychedelics such as and . These substances function as agonists at serotonin 5-HT2A receptors, leading to reproducible alterations in , mood, and cognition that underpin the core experiential elements of psychedelia. Unlike broader categories of hallucinations, which may arise from diverse etiologies including or , psychedelic-induced states emphasize multimodal sensory integration and heightened cortical excitability without inherent . The scope of psychedelia is bounded by its empirical linkage to these neuropharmacological effects, encompassing stylistic expressions in , , and that replicate substance-induced phenomena like visual tracers, geometric patterns, and cross-modal perceptions, but excluding non-pharmacological or abstract movements lacking direct evocation of such chemically mediated states. This delineation prioritizes causal realism from receptor-level interactions over interpretive mysticism, as evidenced by consistent reports of synesthetic blending and perceptual fluidity under controlled administration of 5-HT2A agonists. In contrast to entheogens, which frame similar substances within or divinatory contexts emphasizing encounters with the divine, psychedelia maintains a focus on perceptual and aesthetic dimensions grounded in observable brain dynamics rather than transcendental narratives. This distinction underscores psychedelia's subcultural manifestations as extensions of empirically verifiable altered , rather than ritualistic or ideological pursuits.

Historical Development

Ancient and Indigenous Roots

Archaeological evidence indicates that psilocybin-containing mushrooms were employed in Mesoamerican ritual contexts as early as 3000 BCE, with mushroom-shaped stone artifacts discovered in ceremonial sites across , , and , often interpreted as symbolic representations of psychoactive fungi used for and religious rites. These findings predate the , where historical accounts from 16th-century Spanish chroniclers, such as , document the consumption of teonanácatl ("flesh of the gods") mushrooms during feasts and prophetic ceremonies to induce visions and communicate with deities, though direct chemical residue analysis remains scarce and reliant on iconographic and ethnohistorical correlations. Such practices, embedded in shamanic traditions among groups like the , involved ingestion for purported spiritual insight, yet lack controlled empirical validation of claimed visionary or therapeutic outcomes, with ethnographic reports subject to cultural interpretation biases. In the , indigenous groups have utilized —a of Banisteriopsis caapi vines and Psychotria viridis leaves containing DMT and beta-carboline alkaloids—for ritual purposes, with the earliest direct archaeological evidence consisting of residues in a 1,000-year-old shamanic pouch from the , dated to approximately 1000 CE and analyzed via to confirm psychoactive compounds. Ethnographic studies among and other tribes describe its use in ceremonies and quests to access ancestral or resolve communal conflicts, potentially fostering through shared , though these accounts derive from observer-dependent fieldwork without pre-colonial residue corroboration in the core Amazon, and claims of universal spiritual efficacy remain unverified by modern pharmacological standards. Earlier inferred use around 1500–2000 BCE relies on indirect anthropomorphic motifs rather than chemical traces, highlighting evidentiary gaps. European folklore sporadically references ergot alkaloids from Claviceps purpurea fungus infecting , linked to outbreaks of ("") in the , causing hallucinations, convulsions, and , as documented in medical histories from 500–1500 CE; however, these were predominantly accidental poisonings rather than deliberate ritual ingestion, with speculative ties to witchcraft trials lacking alkaloid residue proof and contrasting sharply with the intentional shamanic frameworks of indigenous Americas. This discontinuity underscores that pre-modern psychedelic applications were culturally isolated, driven by local rather than a cohesive tradition, and interpretations of evolutionary adaptive roles—such as enhancing group bonding via induced empathy—stem from anthropological hypotheses without fossil or genetic substantiation.

Mid-20th Century Synthesis and Initial Exploration

In 1938, Swiss chemist synthesized diethylamide () at Laboratories in while investigating alkaloids for potential circulatory and respiratory stimulants. On April 16, 1943, Hofmann accidentally ingested a trace amount of during resynthesis, experiencing profound perceptual alterations that led him to intentionally self-administer a dose three days later, confirming its potent psychoactive effects. subsequently distributed to researchers starting in 1949 for psychiatric exploration, including early trials modeling psychosis and probing mental states, with over 2,000 patients treated by the mid-1950s under controlled conditions. In the early 1950s, Canadian psychiatrist conducted experiments with and , administering the substances to alcoholics at Weyburn Hospital in to induce insights potentially disrupting addictive patterns; initial tests on two patients in 1953 yielded promising abstinence rates, prompting larger studies reporting up to 50% sustained sobriety after one year in some cohorts. Osmond coined the term "psychedelic" in a 1956 letter to , deriving it from roots meaning "mind-manifesting" to describe drugs eliciting perceptual expansion without delusion, contrasting pejorative labels like "hallucinogen." Concurrently, the U.S. launched Project in 1953, funding covert experiments through 1973 to explore mind control and interrogation techniques, often without , which exposed ethical hazards including psychological harm and fatalities like that of CIA scientist in 1953. Aldous Huxley's 1954 essay documented his experience under Osmond's supervision, portraying enhanced sensory acuity and philosophical revelations while critiquing ego-bound perception, influencing intellectual interest in psychedelics as tools for expanded consciousness. By 1960, initiated the with Richard Alpert, administering —derived from mushrooms—to volunteers in structured sessions aimed at personality assessment and behavioral change, marking a transition from strictly pharmacological inquiry to guided psychological exploration, though controversies over methodology led to its termination by 1963. These efforts prioritized empirical observation of neurochemical impacts, laying groundwork for therapeutic hypotheses before broader societal adoption.

1960s Counterculture Expansion

The expansion of psychedelia into the 1960s counterculture accelerated through influential figures and events that promoted widespread experimentation with and other hallucinogens among Western youth. popularized the mantra "turn on, tune in, drop out" in a September 1966 spoken-word album and public speeches, framing psychedelic use as a pathway to personal and societal transformation. Ken Kesey's organized the , a series of multimedia parties beginning November 27, 1965, at Ken Babbs' home in , and continuing through 1966 in venues like San Jose and , where attendees ingested amid chaotic sensory experiences featuring live music from the . These events, supplied with high-purity produced by Augustus Owsley Stanley III starting in 1965, disseminated the drug on a scale that enabled an estimated 1.25 million doses by 1967, fueling the nascent hippie scene. By 1967, the district in epitomized this expansion during the "," drawing up to 100,000 young people for communal living, music festivals, and open psychedelic use, with and as central elements. Bands like the and , emerging from the and local venues, incorporated psychedelic influences into their improvisational rock, amplifying the subculture's reach through albums and performances that evoked . This period saw artistic innovations in music and visual expression, yet empirical data linked heavy use to adverse outcomes, including increased emergency room visits for acute psychological distress from "bad trips," where users experienced panic, , or hallucinations requiring medical intervention. Critiques of the movement highlighted causal connections between psychedelic experimentation and social disruptions, including erosion of traditional work ethics and family structures, as youth "dropped out" en masse, contributing to aimless communes and heightened agitation. While fostering creative breakthroughs, the unchecked proliferation correlated with reports of psychological casualties and behavioral excesses, such as public and in , underscoring the trade-offs of prioritizing subjective experience over societal stability.

Decline, Prohibition, and Underground Persistence

The passage of the Comprehensive Drug Abuse Prevention and Control Act in 1970, which included the , classified lysergic acid diethylamide () and as Schedule I substances, indicating a high potential for abuse, lack of accepted medical use in treatment, and absence of accepted safety for use under medical supervision. This scheduling reflected empirical observations of widespread recreational misuse in the late 1960s, including reports of acute psychological distress, , and rare but severe outcomes such as or during unsupervised "bad trips." High-profile incidents, such as the 1969 Tate-LaBianca murders orchestrated by Charles Manson's cult—members of which frequently used to induce suggestibility and —amplified public and legislative concerns about psychedelics facilitating behavior and exploitation. Media coverage in the late and early often emphasized sensational accounts of overdoses, chromosomal damage claims (later debunked), and "freakouts" leading to accidents or , contributing to a causal shift in perception from exploratory tool to risk despite some exaggeration. Epidemiological patterns showed rising emergency room visits for hallucinogen-related issues, with U.S. data indicating thousands of exposures annually by 1970, prompting skepticism toward unverified therapeutic benefits amid evident dependency-like patterns in chronic users seeking repeated perceptual alterations. Internationally, the 1971 extended controls to , , and in Schedule I, mandating signatories to prohibit non-medical production and trade to curb global abuse trajectories observed in the prior decade. Despite prohibition, psychedelic use persisted underground, transitioning from overt countercultural settings to niche subcultures like the emerging scene in the 1980s and 1990s, where and complemented electronic music's repetitive rhythms to enhance sensory immersion, though often secondary to . Events such as , initiated in 1986 on a beach and later relocated to Nevada's , fostered communal experimentation with psychedelics amid art installations and radical self-expression, sustaining a reduced but dedicated persistence without mainstream cultural dominance. largely halted post-1970 due to funding restrictions and ethical scrutiny over abuse risks, with informal underground anecdotes of emerging in the 1990s among tech and creative communities seeking subtle cognitive enhancements without full hallucinatory effects. This era marked psychedelia's retreat from visibility, driven by policy responses to documented harms rather than sanitization of risks, while underground networks preserved selective continuity.

Cultural Manifestations

Music and Sonic Aesthetics

Psychedelic music emerged prominently in the mid-1960s rock scene, characterized by distorted electric guitars, heavy reverb, phasing effects, and incorporation of non-Western instruments like sitars to evoke altered states of consciousness induced by hallucinogens. The Beatles' Sgt. Pepper's Lonely Hearts Club Band, released on June 1, 1967, exemplified this shift with its experimental studio techniques and surreal soundscapes, drawing from LSD experiences that expanded perceptual boundaries and inspired innovative compositions. Similarly, Pink Floyd's debut album The Piper at the Gates of Dawn, recorded in early 1967 amid frontman Syd Barrett's heavy LSD use, featured whimsical, hallucinatory tracks with echoing guitars and modal structures that mirrored drug-induced visions. Subgenres such as emphasized heavier, rawer sounds with prolonged improvised jams and feedback-laden solos, aiming to replicate the intensity of psychedelic trips through sonic overload. Freak folk, a psychedelic-infused variant of , incorporated acoustic elements with droning repetitions and ethereal vocals, tracing roots to experimentation that blended traditional forms with mind-expanding aesthetics. Techniques like extended modal allowed musicians to explore non-linear progressions and hypnotic rhythms, fostering a sense of timeless flux akin to hallucinatory . These innovations influenced subsequent genres, notably 1990s , which adopted layered, pulsating synths and build-ups derived from Goa's hippie-rave scene to simulate psychedelic immersion. Empirical studies link psychedelic substances to heightened via increased semantic priming and , suggesting causal ties to the genre's experimental ethos, though direct musical outputs require further validation. Critics have faulted for prioritizing sensory over substantive engagement, potentially reinforcing withdrawal from societal productivity amid the counterculture's leanings.

Visual Arts and Design

Psychedelic in the developed graphic styles that replicated perceptual alterations reported during and intoxication, such as geometric fractals, melting contours, and trails of motion, often rendered in Day-Glo fluorescent colors to evoke synesthesia-like cross-modal sensations. These motifs drew from user accounts of visual distortions, including enhanced and fluid transformations of forms, rather than purely symbolic abstraction. (EEG) studies corroborate this foundation, showing broadband desynchronization of cortical rhythms under , which correlates with disrupted visual processing and illusory perceptions. Key figures included poster designer , who pioneered undulating, elastic lettering for San Francisco's Fillmore Auditorium concert promotions from 1966 to 1968, creating optical illusions of movement and depth that mimicked hallucinatory fluidity. contributed vibrant, cosmic illustrations blending with psychedelic elements, influencing commercial graphics through motifs of stars, eyes, and warped perspectives. Album covers exemplified these techniques, as in Martin Sharp's 1967 design for Cream's , featuring a of distorted figures and floral explosions in saturated hues to simulate altered depth and color intensity. Applications extended to immersive light shows using oil projections and stroboscopic effects at venues like , synchronizing liquid distortions with performances to amplify audience perceptual shifts. This aesthetic permeated advertising, with Peter Max's Day-Glo imagery appearing in campaigns by 1968, and later informed through fractal-generating algorithms that echoed endogenous hallucinations. While fostering innovation in —evident in expanded color palettes and non-linear compositions—these styles often waned with 1970s , revealing their dependence on cultural associations with substance-induced states rather than enduring perceptual principles.

Literature, Philosophy, and Spirituality

Aldous Huxley's novel Island, published in 1962, depicts a fictional society on the island of Pala where psychedelic substances like moksha-medicine (inspired by mescaline and LSD) facilitate spiritual insight and social harmony, contrasting with dystopian control in his earlier Brave New World. The work integrates Huxley's personal experiments with hallucinogens, portraying them as tools for transcending ego and accessing non-dual awareness, though Huxley himself emphasized disciplined use to avoid delusion. Timothy Leary, Ralph Metzner, and Richard Alpert's : A Manual Based on the Tibetan Book of the Dead, released in 1964, reinterprets the ancient Bardo Thödol as a guide for navigating LSD-induced states, framing the trip as a metaphorical and rebirth of the ego. Leary advocated "set and setting" to maximize positive outcomes, drawing parallels between psychedelic visions and Tibetan descriptions of transitions, yet the manual's subjective interpretations lack empirical validation of ontological claims like universal unity. Philosophically, psychedelic literature promotes concepts of expanded , where —reported as a loss of self-boundaries and sense of oneness—challenges materialist views of isolated minds. Such experiences often induce beliefs in interconnected reality or , with studies showing acute shifts toward non-materialist metaphysics post-use. However, these alterations stem from heightened and neural disruptions rather than evidence of underlying , as subjective phenomenology does not confirm external causal structures like a unified ; critiques highlight risks of solipsistic or delusional inferences, where perceived unity reflects temporary brain entropy, not verifiable truth. In , these texts fueled countercultural narratives of personal , linking psychedelics to Eastern and inspiring movements that equate states with divine . Yet, such fusions often veer into by attributing causal efficacy to untestable metaphysics, contributing to anti-rational trends that prioritized intuitive "insights" over falsifiable evidence, as seen in the era's rejection of scientific rigor for unfettered experientialism. Empirical limits persist: while ego dissolution correlates with serotonin receptor agonism, it proves neither spiritual veracity nor ego's illusory nature, underscoring the need for over metaphysical assertion.

Scientific and Pharmacological Aspects

Key Substances and Neurochemical Mechanisms

Lysergic acid diethylamide (LSD), synthesized by in 1938 as part of research into ergot alkaloids, functions primarily as a at serotonin 5-HT2A receptors, particularly those on neocortical pyramidal cells, leading to altered and . , isolated by Hofmann in 1958 from mushrooms, serves as a metabolized to , which binds to 5-HT2A receptors and other serotonin subtypes, inducing similar hallucinogenic profiles through enhanced excitatory signaling in cortical regions. , a derived from ( williamsii) cactus, acts as an agonist at 5-HT2A and 5-HT2C receptors, with its core perceptual distortions mediated via 5-HT2A activation, though it exhibits lower potency and longer onset compared to tryptamines. N,N-Dimethyltryptamine (DMT), a found in plants used in brews, elicits rapid, intense effects through 5-HT2A agonism when administered via inhalation or combined with inhibitors (MAOIs) to enable oral , resulting in short-duration (5-15 minutes standalone) immersion in vivid visual phenomena. These classical psychedelics share a common neurochemical signature of preferential 5-HT2A receptor stimulation, which modulates glutamate release in layer V pyramidal neurons of the , amplifying signal-to-noise ratios in sensory hierarchies without direct or opioidergic involvement. Functional neuroimaging, including fMRI, reveals that this receptor activation disrupts the (DMN)—a set of interconnected regions including the posterior cingulate and medial associated with self-referential thought—by reducing its integrity and increasing global brain , as observed in studies with and where decreased DMN connectivity correlates with subjective dissolution of ego boundaries. While endogenous DMT occurs in trace amounts in mammalian brains, including humans, no supports it generating spontaneous psychedelic states under physiological conditions, distinguishing exogenous administration's supraphysiological receptor occupancy from baseline . Synthetic variants like , a analog, similarly target 5-HT2A but with additional affinity for 5-HT2C and adrenergic sites, yielding milder, shorter effects distinct from the prolonged introspection of (typically 8-12 hours).

Psychological and Physiological Effects

Psychedelics like , , and primarily act as agonists at serotonin 5-HT2A receptors, leading to acute psychological effects that include perceptual distortions such as visual hallucinations, , and enhanced pattern recognition, alongside cognitive shifts like and altered sense of . Experiences of ego dissolution—characterized by a temporary loss of subjective boundaries between and environment—and profound ranging from to introspection are also reliably reported across controlled and naturalistic settings. These alterations typically onset within 30-90 minutes, peak at 2-4 hours, and resolve within 6-12 hours depending on the substance and dose. Physiologically, classic psychedelics elicit moderate autonomic activation, including (pupil dilation), (elevated ), , and slight increases in body temperature and blood glucose. For instance, tends to produce greater diastolic elevations compared to equivalent doses of or , while induces more pronounced increases. These effects stem from downstream noradrenergic and modulation rather than direct sympathomimetic action, and at standard doses (e.g., 100-200 μg or 20-30 mg ), no acute lethality has been documented due to their high and lack of respiratory depression. Nonetheless, they can exacerbate underlying conditions; for example, in individuals with latent psychotic disorders like , psychedelics may trigger acute exacerbations or prolonged via heightened dopamine-serotonin interactions. Adverse acute psychological outcomes occur in a minority of cases, manifesting as anxiety, depersonalization, or —often termed "bad trips"—with incidence influenced by dose, expectancy, and concurrent stressors. Chronic risks include (HPPD), where users experience recurrent visual phenomena like trails, halos, or geometric patterns persisting for months or years post-use; epidemiological estimates place its prevalence at around 4% among those with exposure, though underreporting and diagnostic variability complicate precise figures. Response variability is substantial, with empirical data supporting the 1960s conceptualization of "set" (user's mindset and expectations) and "setting" (environmental context) as modulators of effect intensity and valence—for example, supportive genres in controlled sessions reduce anxiety compared to neutral conditions. However, causal factors extend to , including polymorphisms in serotonin receptor genes (e.g., HTR2A) that alter drug potency and subjective intensity, underscoring that uniform psychological outcomes or purported benefits cannot be assumed without accounting for these individual differences.

Therapeutic Research and Applications

Early Clinical Investigations

In the 1950s, researchers such as Humphry Osmond and Abram Hoffer initiated clinical trials using LSD to treat chronic alcoholism, administering single high doses in psychotherapeutic settings to induce profound experiential shifts. Osmond's studies, beginning around 1953, involved small cohorts of alcoholics, with initial reports indicating approximately 50% achieving sustained abstinence for at least six months post-treatment, though sample sizes were limited to fewer than 10 patients in early phases. By the late 1950s, Osmond and Hoffer expanded to treat around 2,000 alcoholics between 1954 and 1960, documenting 40-45% remaining abstinent after one year, based on follow-up self-reports that highlighted insights into addictive behaviors. These outcomes were preliminary and uncontrolled, relying on subjective patient narratives without placebo comparisons or blinding, which introduced expectancy biases. Hoffer and Osmond also explored 's capacity to mimic schizophrenic symptoms, positing it as a biochemical model for the disorder through adrenochrome hypotheses linking hallucinogens to endogenous toxins. In Saskatchewan-based experiments from the early 1950s, they administered to patients and healthy volunteers to replicate psychosis-like states, observing perceptual distortions and thought disorders akin to , which informed theories of metabolic imbalances in mental illness. Hoffer's self-experiments with and further validated this model psychosis approach, though results depended heavily on unblinded observations and lacked rigorous quantification of symptom fidelity to natural . Timothy Leary's in the early 1960s extended investigations to attitude and behavioral modification, including the 1961 with 32 inmates receiving -assisted therapy to foster prosocial shifts and reduce . Follow-up data suggested lower reoffense rates compared to matched controls, attributed to enhanced self-concordance in values and emotional processing, but the study's open-label design and small scale precluded causal attribution. Similarly, the 1962 Good Friday Experiment administered to 10 of 20 students during a religious service, yielding reports of intensified mystical experiences versus , with participants describing unity and that correlated with enduring attitudinal changes. Early applications extended to potential enhancements in creativity and relief from or anxiety, with over 40,000 patients treated with variants by 1965 for neuroses, often reporting acute mood elevations and insight-driven symptom reductions in uncontrolled sessions. However, these findings were undermined by methodological shortcomings, including overreliance on self-reported outcomes, high dropout rates unaccounted for in analyses, and absence of double-blind protocols, which amplified effects and researcher expectations. Such flaws, while yielding intriguing preliminary signals for therapeutic utility, highlighted the need for more robust empirical validation absent in the era's exploratory paradigm.

Prohibition-Era Interruptions and Resumptions

Following the enactment of the U.S. in 1970, which classified psychedelics such as , , and as Schedule I substances—indicating high abuse potential and no accepted medical use—federal funding for research effectively ceased for decades. This policy shift, driven by concerns over recreational misuse and countercultural associations, imposed stringent regulatory barriers, including approvals and ethical reviews, that discouraged institutional participation and halted most clinical investigations. By the mid-1970s, government-sponsored studies dwindled to near zero, creating a void in empirical data on long-term effects and therapeutic potential, as prior research from the and lacked the methodological rigor of modern randomized controlled trials. Isolated efforts persisted in the amid this stagnation, exemplified by psychiatrist Rick Strassman's federally approved studies at the from 1990 to 1995, marking the first human trials with hallucinogens in over two decades. These intravenous DMT administrations to 60 volunteers focused on dose-response effects, physiological monitoring (e.g., , hormone levels), and subjective reports of profound spiritual or otherworldly experiences, revealing rapid onset and short duration but underscoring gaps in understanding endogenous roles of such compounds. Such analog research highlighted regulatory feasibility for niche academic work but remained exceptional, limited by funding scarcity and institutional risk aversion, with no comparable large-scale programs emerging until later advocacy. Resumption gained traction through nonprofit initiatives, notably the founding of the (MAPS) in 1986 by , prompted by MDMA's emergency Schedule I placement in 1985. MAPS prioritized for PTSD, securing initial FDA approvals for animal toxicity studies by the early and funding human trials despite repeated rejections, emphasizing rigorous protocols to rebuild scientific credibility. Doblin's persistence, rooted in , bridged prohibition-era gaps by resources and challenging bureaucratic inertia, though progress was incremental and confined to specific substances. These interruptions resulted in of data accumulation, impeding causal insights into neurochemical mechanisms and therapeutic efficacy, as prioritized risk mitigation—based on anecdotal abuse reports—over exploratory , potentially averting unverified harms but also obstructing and evidence-based refinements. Critics argue the policy's blanket restrictions censored empirical progress, fostering evidentiary voids that persist, while proponents contend it safeguarded against insufficiently vetted interventions amid sparse pre-1970 controls. This tension underscores how regulatory , absent adaptive review of emerging data, amplified gaps rather than resolving safety uncertainties through iterative study.

21st-Century Trials and Empirical Outcomes

In the , randomized controlled trials (RCTs) of psychedelic-assisted therapies have primarily focused on , , and for conditions like (TRD), (MDD), and (PTSD), with outcomes showing rapid symptom reductions but moderated by methodological constraints. A landmark 2016 Johns Hopkins RCT involving high-dose for cancer-related anxiety and reported large, sustained decreases in clinician- and self-rated depressive mood and anxiety scores, with 80% of participants showing clinically significant improvements persisting up to six months post-treatment. Follow-up data from this cohort indicated sustained remission in subsets, with 67% maintaining response for at least five years in long-term analyses. The U.S. (FDA) granted designation to for PTSD in 2017 based on phase 2 evidence of efficacy, expediting development. Similarly, received FDA breakthrough designations for TRD in 2018 (Compass Pathways) and MDD in 2019 (Usona ), reflecting preliminary RCT data on effects. Meta-analyses of psilocybin RCTs from 2020–2024, aggregating data from nine studies (n=596), have demonstrated moderate to large effect sizes for depressive symptom reduction (standardized mean difference [SMD] = -0.78; p<0.001), with response rates favoring over comparators and remission in 50–70% of participants at 4–12 weeks. For in PTSD, phase 3 RCTs (e.g., MAPP1, 2021) reported 67% achieving clinically significant symptom reduction versus 32% in groups, with effects lasting up to 18 months in open-label extensions. LSD-assisted therapy trials for anxiety, including a 2025 RCT, showed single-dose effects reducing symptoms for months, though with high inter-individual variability. Overall, these outcomes indicate acute in TRD and anxiety subsets, but effect sizes diminish over time without maintenance dosing, and responses pose challenges due to poor blinding from profound subjective effects. Adverse events in these RCTs occur in approximately 10–20% of participants, typically mild (e.g., transient anxiety, ), but include serious risks such as acute suicidality spikes or exacerbated in vulnerable individuals. trials report no overall increase in suicidality long-term, yet isolated cases of or attempts during integration phases highlight causal uncertainties. sessions carry cardiovascular risks from sympathomimetic effects, with jaw clenching and transient in up to 30% of cases. Key limitations across trials include small sample sizes (often n<50 per arm), reducing statistical power and generalizability, and potential bias from unblinded delivery influencing expectancy effects. High placebo response rates in control arms—exceeding those in SSRI trials—underscore blinding failures, as active drugs produce unmistakable perceptual alterations. Recent pharmaceutical investments, such as AbbVie's 2025 $1.2 billion acquisition of Pharmaceuticals' bretisilocin (a analog for MDD), signal commercialization momentum but precede comprehensive long-term safety data beyond 2–5 years. These deals prioritize scalable formulations over integration, raising concerns about diluted efficacy without sustained empirical validation.

Legal and Regulatory Landscape

Historical Legislation and Bans

In the United States, initial restrictions on lysergic acid diethylamide () emerged at the state level in 1966, with and enacting the first bans on its sale amid concerns over unregulated distribution and associated public health incidents. Federally, the Drug Abuse Control Amendments of 1965 were expanded in 1966 via the Grunsky Bill, which prohibited the possession, manufacture, and sale of , responding to its rapid proliferation in recreational contexts following widespread countercultural experimentation. These measures were driven by epidemiological observations of escalating youth involvement, including reports of adverse psychological reactions and accidental injuries under the influence, though direct overdose fatalities from remained rare due to its low physiological toxicity. The Comprehensive Drug Abuse Prevention and Control Act, enacted in 1970 as the (), formalized the scheduling of psychedelics including , , and in Schedule I, criteria requiring demonstration of high abuse potential, absence of accepted medical use, and lack of safety for administration under medical supervision. This classification contrasted with substances like and , which evaded similar controls despite comparable or greater societal harm metrics, owing to their cultural entrenchment and economic scale rather than superior safety profiles. Legislative impetus drew from data on rising use among college populations—such as surveys indicating increased campus incidents—and documented cases of impaired judgment leading to casualties, prioritizing containment of non-medical proliferation over prior exploratory psychiatric applications. Internationally, the of 1971 harmonized controls by listing , , and related compounds in its most restrictive schedules, mandating signatory nations to prohibit non-medical production and trade to curb cross-border trafficking fueled by demand surges. These prohibitions effectively suppressed authorized recreational and experimental access, correlating with declines in reported legal use, yet fostered persistent black markets that sustained underground supply chains undeterred by enforcement. The Schedule I assertion of negligible therapeutic utility, embedded in both U.S. and UN frameworks, has faced subsequent scrutiny against early-20th-century clinical data suggesting potential , highlighting tensions between precautionary and evolving evidentiary standards.

Contemporary Decriminalization and Reform Efforts

In May 2019, voters approved Initiative 301, making the city the first to decriminalize the possession and use of mushrooms by directing to treat such activities as their lowest enforcement priority. In November 2020, voters passed Measure 109, establishing a regulated program for supervised administration in licensed service centers for adults 21 and older, with operations commencing in summer 2023 under the Oregon Health Authority. These measures represent early local precedents for shifting from to limited therapeutic or deprioritized access, though continues to classify as a Schedule I substance. Advocacy organizations such as the (MAPS) have driven reform by funding clinical research and pushing for evidence-based policy pathways, including support for FDA-reviewed protocols. Similarly, The Third Wave has promoted education and vetted provider networks to foster responsible integration amid efforts. By 2025, over 36 bills in more than a dozen states addressed psychedelics, focusing on research acceleration, medical access, and , though most failed to pass, with examples including New Jersey's S2283 for behavioral health services and New York's proposals for screened therapeutic use. These initiatives highlight a patchwork of state-level momentum, often tied to ongoing clinical trials, but critics argue that rapid risks exacerbating inequities by sidelining traditional knowledge systems, where substances like originate, without incorporating tribal consultation or addressing historical disenfranchisement in Western commercialization models. Federal prospects remain cautious, as evidenced by the FDA's August 2024 rejection of Lykos Therapeutics' MDMA-assisted therapy application for PTSD due to insufficient evidence of efficacy, potential biases in trial data, and inadequate safeguards against abuse or cardiovascular risks. No psychedelic therapies have received FDA approval as of October 2025, with pending Phase 3 trials for in underscoring the need for rigorous, gated access—such as supervised settings with pre-screening—over broad , which could normalize unsupervised use absent robust empirical validation of long-term safety and equity. This approach prioritizes causal mechanisms linking controlled administration to therapeutic outcomes while mitigating risks of unregulated proliferation.

Societal Impacts and Debates

Claimed Benefits and Cultural Contributions

Psychedelics contributed to the emergence of in 1966, a genre featuring experimental sounds and extended improvisations that reflected altered states of consciousness and influenced bands like The Grateful Dead and . This musical innovation paralleled developments in , where artists employed swirling patterns, optical illusions, and fluorescent colors to evoke hallucinatory experiences, as seen in posters for events like the in 1967. These cultural expressions challenged mid-20th-century artistic norms and promoted nonconformity within the . Proponents attribute to psychedelics a role in amplifying anti-war sentiments during the era, positing that expanded perceptions fostered and opposition to , though direct causation is contested amid confounding factors such as graphic war footage on television and draft policies. Similarly, psychedelic experiences are claimed to heighten environmental awareness by dissolving ego boundaries and enhancing interconnectedness with nature, with empirical studies showing acute increases in nature relatedness following or use. Controlled trials demonstrate that occasions mystical experiences associated with sustained increases in the personality trait of , measured via the NEO-PI-R inventory, persisting up to 14 months post-administration in healthy volunteers. This shift is hypothesized to underpin claims of enhanced and innovation, as correlates with ; however, acute psychedelic states may temporarily impair convergent creativity tasks, with post-acute benefits more evident in self-reports and associative measures. Such changes suggest potential for breaking entrenched cognitive patterns, though long-term societal impacts remain correlational rather than conclusively causal.

Criticisms, Risks, and Empirical Shortcomings

Psychedelics pose notable risks of precipitating acute psychotic episodes or exacerbating underlying vulnerabilities, particularly in susceptible populations. A population-based of over 9.2 million individuals in , , from 2008 to 2021 linked use (including , , and DMT) to a significantly elevated risk of subsequent , with ratios indicating up to a 21-fold increase following emergency department visits related to exposure. Individuals with genetic or familial predispositions to or face amplified dangers, as psychedelic use correlates with heightened manic or psychotic symptoms in these groups, prompting routine exclusion of such patients from clinical trials. These effects stem from psychedelics' disruption of serotonin signaling and integrity, potentially unmasking latent psychopathologies rather than resolving them. Empirical claims of broad therapeutic efficacy have faced scrutiny for inconsistent replication and overreliance on small-scale, non-blinded studies from the mid-20th century. By the , initial optimism surrounding LSD-assisted diminished as larger-scale efforts, such as those at Spring Grove State Hospital, yielded variable outcomes influenced by set, setting, and operator variability, failing to consistently outperform control conditions or secure regulatory approval beyond anecdotal successes. Modern trials, while promising in controlled environments, often overlook long-term durability, with dropout rates and non-response exceeding 30% in some protocols for , highlighting methodological shortcomings like subjective outcome measures and favoring positive results. Population-level data post-decriminalization, such as in (Measure 109, 2020) and (2019 ordinance), show doubled adult use without corresponding reductions in burdens or societal indicators like rates, instead correlating with rising adverse event reports requiring medical in over 50% of tracked exposures. The 1960s counterculture's recreational proliferation of psychedelics has drawn for fostering escapist ideologies that prioritized perceptual novelty over disciplined , contributing to the of rigorous scientific progress in favor of unstructured excess. This era's association with widespread misuse amplified perceptions of psychedelics as tools for evasion rather than enhancement, eroding institutional trust and stalling empirical validation for decades. Emerging commercialization introduces further perils, as for-profit entities funding research risk subordinating evidence-based protocols to market-driven narratives, with financial ties potentially inflating efficacy estimates and underreporting harms like . Such dynamics mirror historical patterns where hype outpaced causal substantiation, underscoring the need for independent oversight to mitigate profit motives eclipsing and replicable outcomes.

Ethical and Cultural Appropriation Concerns

Critics argue that the Western adoption of psychedelics like and often divorces these substances from their ceremonial contexts, which include safeguards such as dietary preparations, preparation, and communal , potentially increasing risks of adverse psychological experiences. In tourism, particularly in the , participants frequently encounter ceremonies led by non- facilitators lacking traditional training, leading to reports of intensified challenging psychological effects without the mitigating cultural protocols. Similarly, 's extraction from traditions has been described as involving and cultural appropriation, where sacred fungi are commodified without reciprocal benefits to originating communities. The psychedelic renaissance has drawn accusations of neocolonialism, with Western researchers and entrepreneurs profiting from traditional knowledge—such as patents on psilocybin derivatives—while indigenous groups receive minimal compensation or consultation, echoing historical patterns of resource extraction. For instance, North American and European entities have secured intellectual property rights on psychedelic compounds derived from indigenous sources, generating billions in market value projected from $3.8 billion in 2020, yet without equitable revenue sharing. Academic analyses liken this to colonial extractivism, where the "renaissance" mirrors European precedents by leveraging non-Western ontologies for modern therapeutic gains absent reciprocity. Clinical trials exacerbate equity issues through participant demographics that skew heavily toward non-Hispanic white individuals, comprising approximately 80% of enrollees across 20 studies from 2006 to 2023, compared to their 60% share of the U.S. . /African-American stands at just 2.2%, far below their 13.6% population proportion and even lower than in non-psychedelic trials, limiting generalizability and perpetuating disparities in access to potential benefits. Ethical challenges in psychedelic therapy include difficulties with , as the drugs' unpredictability can impair decision-making capacity during sessions, complicating ongoing affirmation of participation amid . Unique properties, such as profound subjective transformations and potential for ego dissolution, demand enhanced consent protocols beyond standard medical models, including repeated assessments and disclosure of risks like persistent perceptual changes. While these concerns highlight the need for rigorous, evidence-based safeguards prioritizing causal mechanisms of over unsubstantiated cultural narratives, empirical underscore that therapeutic utility derives from controlled administration rather than obligatory emulation.

Recent Developments and Trajectories

Research Renaissance Post-2010

Following the groundwork laid by early 21st-century investigations, psychedelic research accelerated after 2010, with a marked increase in clinical trials examining compounds like and for applications. The (MAPS) advanced for (PTSD), culminating in phase 3 trials by the mid-2010s that reported significant symptom reductions in participants, though subsequent FDA review in 2024 highlighted methodological concerns including potential bias in subjective outcome measures. studies, building on prior research, expanded to target and anxiety, with trials demonstrating rapid antidepressant effects in treatment-resistant cases, albeit with small sample sizes limiting generalizability. By the 2020s, the field saw a surge in activity, with over 100 ongoing clinical trials registered globally by 2025, focusing on conditions such as and end-of-life anxiety. Key milestones included the FDA's March 2024 breakthrough therapy designation for lysergide d-tartrate ( derivative) in , based on phase 2 data showing efficacy comparable to established anxiolytics. Research into neuroplasticity mechanisms advanced concurrently, revealing that psychedelics like and promote dendritic spine growth and synaptic remodeling via agonism and increased (BDNF) expression, potentially underlying observed therapeutic persistence beyond acute effects. However, these findings derive largely from preclinical models and early human imaging studies, with human trial replication inconsistent due to variability in dosing and set-and-setting factors. Population-level psychedelic use rose in parallel, with past-year hallucinogen prevalence among U.S. adults aged 19-30 reaching 9% in 2023, driven predominantly by psilocybin (approximately 8 million users overall). This uptick coincided with the post-COVID-19 mental health crisis, characterized by elevated rates of anxiety, depression, and PTSD, prompting hypotheses that societal distress fueled research interest and self-medication trends. Empirical data show correlations between psychedelic use and self-reported improvements in mood during the pandemic, yet causal inference is confounded by selection bias—users often exhibit higher baseline resilience—and some longitudinal analyses indicate no net superiority over non-drug therapies or risks of adverse psychological events in vulnerable populations. Academic enthusiasm, potentially amplified by funding from advocacy groups, underscores the need for rigorous, double-blind controls to disentangle pharmacological effects from expectancy.

Commercialization and Mainstream Integration

The psychedelic therapeutics market has expanded significantly, with projections estimating a value of USD 4.08 billion in 2025, growing to USD 7.75 billion by 2030 at a (CAGR) of 13.69%, driven primarily by clinical development pipelines for substances like and . Major pharmaceutical firms have pursued investments and acquisitions, including & Johnson's 2019 FDA approval of (Spravato) as a for , marking an early commercial entry into psychedelics, and Otsuka Pharmaceutical's 2023 acquisition of Mindset Pharma for approximately USD 58 million to advance derivatives targeting neurological disorders. Integration into mainstream sectors includes the proliferation of retreats offering guided psychedelic experiences, often in jurisdictions with , such as and , where operators charge USD 2,000–10,000 per session for purported and personal growth outcomes, though these frequently rely on anecdotal reports rather than large-scale randomized controlled trials (RCTs). products and apps, promoting sub-perceptual doses of lysergamides or analogs for productivity enhancement, have entered consumer markets via sales and subscription models, with limited peer-reviewed evidence supporting sustained cognitive or mood benefits beyond effects. Corporate initiatives have tested psychedelic retreats for executive stress reduction and team cohesion, as seen in pilots by tech firms organizing supervised sessions in retreat settings, amid claims of improved but with scant longitudinal data on outcomes or risks. Commercialization introduces risks of unevidenced claims, where marketing emphasizes transformative potential based on small II trials or self-reported data, potentially echoing the crisis in which pharmaceutical firms overstated non-addictive properties of drugs like OxyContin, leading to over 500,000 overdose deaths in the U.S. from 1999 to 2021 through aggressive promotion ahead of full safety profiles. Regulatory challenges include high administration costs—estimated at USD 1,500–3,000 per therapy session due to required clinical oversight—and hurdles, as insurers demand III RCT evidence for coverage, while lobbying for expedited approvals raises concerns of capture prioritizing over rigorous post-market . Future viability hinges on RCTs confirming targeted efficacy, such as psilocybin's 67% response rate in from 2021–2023 trials, but parallels to overpromising underscore the need for causal validation of benefits against risks like or psychological dependency in non-clinical contexts.

References

  1. [1]
    Psychedelics - PMC - PubMed Central - NIH
    Psychedelics (serotonergic hallucinogens) are powerful psychoactive substances that alter perception and mood and affect numerous cognitive processes.
  2. [2]
    Psychedelics - Alcohol and Drug Foundation
    Jun 6, 2025 · Psychedelics (also known as hallucinogens) are a class of psychoactive substances that produce changes in perception, mood and cognitive processes.
  3. [3]
    The Origin of the Term “Psychedelic” - NYAS
    Apr 4, 2024 · The man who is known to have supplied author Aldous Huxley with hallucinogenic drugs publicly coined the word “psychedelic” during an Academy event in 1957.
  4. [4]
    The Therapeutic Potential of Psychedelic Drugs: Past, Present, and ...
    May 17, 2017 · The subjective effects of the high dose consisted in heightened states of consciousness with marked emotional accompaniments (anxiety, ...Missing: empirical | Show results with:empirical
  5. [5]
    Study explores the enduring positive, negative consequences of ...
    Jan 4, 2017 · Study explores the enduring positive, negative consequences of ingesting 'magic mushrooms'. Johns Hopkins researchers surveyed nearly 2,000 ...
  6. [6]
    Psychedelic and Dissociative Drugs | National Institute on Drug Abuse
    Psychedelic and dissociative drugs can temporarily alter a person's mood, thoughts, and perceptions. Among other health effects and safety concerns, ...
  7. [7]
    Extended difficulties following the use of psychedelic drugs
    Long-term adverse experiences following psychedelic use can persist for weeks, months, or even years, and are relatively unexplored in psychedelic research.
  8. [8]
    Psychedelic medicine: a re-emerging therapeutic paradigm - PMC
    Researchers in the 1950s and 1960s studied the use of psychedelic-assisted therapy for the treatment of addictions such as alcohol dependence, some key findings ...
  9. [9]
    Adverse effects of psychedelics: From anecdotes and misinformation ...
    This narrative review examines the evidence for potential harms of the classic psychedelics by separating anecdotes and misinformation from systematic research.
  10. [10]
    The Therapeutic Potential of Psychedelic Drugs: Past, Present, and ...
    Apr 26, 2017 · Plant-based psychedelics, such as psilocybin, have an ancient history of medicinal use. After the first English language report on LSD in ...<|separator|>
  11. [11]
    The historical opposition to psychedelic research and implications ...
    Nov 21, 2024 · Throughout history, psychedelic research has evolved alongside opposition and controversy, including questionable scientific practices, ...
  12. [12]
    The Letters of Aldous Huxley and Humphry Osmond - ResearchGate
    Sep 26, 2025 · ... Humphry Osmond coined the term "psychedelic" in 1956. 35 Huxley soon developed the idea that psychedelic experience could be of prime ...
  13. [13]
    Psychedelic - Etymology, Origin & Meaning
    Originating from Greek psykhē (mind) + dēloun (reveal), psychedelic means "producing expanded consciousness through heightened awareness," coined in 1956 by ...Missing: delos | Show results with:delos
  14. [14]
    What Is Psychedelic Experience? - Oxford Academic
    Oct 19, 2023 · Another common term in use was 'psychotomimetic', indicating that these drugs produce psychological states that resemble psychosis. Osmond ...
  15. [15]
    Psychedelics and Consciousness: Distinctions, Demarcations, and ...
    When scientific research began on psychedelics in the mid-20th century, they were initially studied for their potential “psychotomimetic” properties (i.e., ...
  16. [16]
    Psychedelics - History of Medicine - Oxford Bibliographies
    Apr 17, 2025 · Psychedelic substances are associated with plants, fungi, animals, and synthetic substances that can cause changes in consciousness and hallucinations.Missing: credible | Show results with:credible
  17. [17]
    Design Rewind: Psychedelic Design - Karalyte
    Apr 12, 2023 · Wes Wilson, 1966. Wilson is considered the father of the psychedelic poster. Otis Rush & His Chicago Blues Band. Wes Wilson ...
  18. [18]
    Psychedelics promote neuroplasticity through the activation of ...
    Feb 16, 2023 · Psychedelics are 5-hydroxytryptamine (serotonin) 2A receptor (5-HT2AR) agonists that can lead to profound changes in perception, cognition, and ...
  19. [19]
    Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling ...
    Studies indicate that several effects of hallucinogens involve agonist activity at the serotonin 5-HT 2A receptor.
  20. [20]
    Psychedelics reopen the social reward learning critical period - Nature
    Jun 14, 2023 · Psychedelics are a broad class of drugs defined by their ability to induce an altered state of consciousness1,2. These drugs have been used ...
  21. [21]
    Hallucinations Under Psychedelics and in the Schizophrenia ...
    Sep 18, 2020 · We also highlighted various crucial differences: First, psychedelics over-engage primary sensory cortices, hallucinations in SCZs, on the other ...Missing: entheogens | Show results with:entheogens
  22. [22]
    Synesthetic hallucinations induced by psychedelic drugs in a ...
    Psychedelics can induce synthetic synesthesia, aphasia and distort time perception. •. Novel sensory experiences arise in psychedelic drug use in congenital ...
  23. [23]
    Serotonergic Hyperactivity as a Potential Factor in ... - Frontiers
    Drug-induced synesthesia is a blending of perceptual or cognitive streams that emerges in subjects under the influence of psychedelic hallucinogens, ...Missing: distortion | Show results with:distortion
  24. [24]
    Serotonergic Psychedelics: Experimental Approaches for Assessing ...
    Since then, numerous groups have shown that serotonergic psychedelics elicit the behavior via a 5-HT2A mechanism. Tested psychedelics include LSD, psilocybin ...
  25. [25]
    Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the ...
    Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport, 9 (17) (1998), pp. 3897-3902, 10.1097/00001756 ...
  26. [26]
    Entheogens vs. Psychedelics: What is The Difference? - PsyPost
    Range of Substances: While entheogens are typically natural substances, the category of psychedelics includes both natural and synthetic compounds.
  27. [27]
    Entheogens and Psychedelics (including Ayahuasca, LSD, Peyote ...
    Dec 16, 2023 · "An entheogen is a psychoactive compound, typically from natural sources such as plants or fungi, that can be used to alter consciousness ...
  28. [28]
    Psychedelics - ScienceDirect.com
    Jan 24, 2022 · The term 'psychedelic', from the Greek for mind manifesting, refers to the drugs' subjective effects and was first proposed by Humphry Osmond in ...Missing: credible | Show results with:credible
  29. [29]
    Hallucinogenic drugs in pre-Columbian Mesoamerican cultures
    Mushroom stones dating from 3000 BC have been found in ritual contexts in Mesoamerica. Archaeological evidence of peyote use dates back to over 5000 years.
  30. [30]
    Hallucinogenic drugs in pre-Columbian Mesoamerican cultures
    Several 16th-century historians (Durán, Sahagún, and Motolinía) described Aztecs using sacred mushrooms during their religious ceremonies. In Historia de las ...
  31. [31]
    Ritual and Religious Uses of Psilocybe Mushrooms in Mesoamerica
    Oct 9, 2024 · Cultural data, however, is plentiful. Archaeological and historical evidence suggests that psilocybe mushrooms were used in Mesoamerica as early ...
  32. [32]
    Ancient ayahuasca found in 1,000-year-old shamanic pouch
    May 6, 2019 · A small pouch, made from three fox snouts neatly sewn together, may contain the world's earliest archaeological evidence for the consumption of ayahuasca.
  33. [33]
    Ayahuasca fixings found in 1,000-year-old Andean sacred bundle
    May 6, 2019 · The remarkably well-preserved ritual bundle was found by archaeologists at 13,000-foot elevations in the Lipez Altiplano region of southwestern ...
  34. [34]
    Ancient psychoactive plants in a global village: The ritual use of ...
    This paper aims to explore drug use rituals as methods of community-controlled use that help maintain a self-regulated and healthy relation to the substance in ...
  35. [35]
    History of ergot alkaloids from ergotism to ergometrine - PubMed
    They were a source of inspiration for artists and were popularly known as 'St. Anthony's Fire', resulting in gangrene, neurological diseases and death. It was ...Missing: folklore | Show results with:folklore
  36. [36]
    Introduction: Evidence for entheogen use in prehistory and world ...
    Jun 1, 2019 · Ethnographic accounts reveal repetitive features associated with the ritual use of psychedelics in cultures around the world (Dobkin de Rios, ...
  37. [37]
    LSD Synthesis and Discovery: What You May Not Know About It
    When it was discovered by Sandoz Laboratories, the purpose was using LSD as a respiratory and circulatory stimulant. It was found while analyzing organic ...
  38. [38]
    Hallucinogenic effects of LSD discovered | April 16, 1943 - History.com
    In Basel, Switzerland, Albert Hofmann, a Swiss chemist working at the Sandoz pharmaceutical research laboratory, accidentally consumes LSD-25, a synthetic ...
  39. [39]
    Modern Clinical Research on LSD | Neuropsychopharmacology
    Apr 27, 2017 · From 1949 to 1966, LSD (Delysid, LSD 25) was provided to psychiatrists and researchers 'to gain insights into the world of mental patients' and ...<|control11|><|separator|>
  40. [40]
    Psychiatric Experimentation with LSD in Historical Perspective
    In 1953, Hoffer and Osmond tested their theory by treating 2 patients suffering from chronic alcoholism with LSD. ... treatment of alcoholism: the hallucinogenic.
  41. [41]
    PROJECT MK-ULTRA | CIA FOIA (foia.cia.gov)
    Project MK-ULTRA, MK-ULTRA, or MKULTRA, was the code name for a covert CIA mind-control and chemical interrogation research program, run by the Office of ...
  42. [42]
    When Aldous Huxley Opened the Doors of Perception
    Dec 20, 2021 · ... mescaline and similar drugs would be used for intellectual and spiritual education. For Huxley, mescaline and drugs like it represented ...<|separator|>
  43. [43]
    [PDF] Timothy Leary's legacy and the rebirth of psychedelic research
    ... Harvard in the fall of 1960, Leary teamed up with Alpert, an assistant professor and popular lecturer, and launched the Harvard Psilocybin Project. Graduate ...
  44. [44]
    https://www.discogs.com/release/1230839-Timothy-Leary-PhD-Turn-On-Tune-In-Drop-Out
  45. [45]
    The Acid Tests - Origins: Current Events in Historical Perspective
    Dec 5, 2015 · The first Test took place on December 4, 1965 in San Jose, California and the last two occurred in San Francisco on October 2 and 31, 1966 when ...
  46. [46]
    Owsley Stanley: The King of LSD - Rolling Stone
    Mar 14, 2011 · Owsley was already an authentic underground folk hero, revered throughout the counterculture for making the purest form of LSD ever to hit the street.Missing: history | Show results with:history
  47. [47]
    The San Francisco Scene, 1967 - TeachRock
    The 1967 San Francisco scene, known as the "Summer of Love," saw 100,000 young people, with free attitudes towards love, art, and drugs, and music with ...Overview · Procedure · Common Core State Standards
  48. [48]
    https://foundsf.org/index.php?title=Jefferson_Airplane_and_the_Psychedelic_1960s
  49. [49]
    Adverse experiences resulting in emergency medical treatment ...
    Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD) ... bad trips on psychedelics. Journal ...
  50. [50]
    Psychedelic drugs, hippie counterculture, speed and phenobarbital ...
    The 1960s were a time of social upheaval, wars, vibrant creativity and missed opportunity ... Psychedelic drugs, hippie counterculture, speed and phenobarbital ...
  51. [51]
    [PDF] Adverse experiences resulting in emergency medical treatment ...
    Lysergic acid diethylamide (LSD) is a potent psychedelic drug. Like all ... '60s is believed to have contributed to more 'bad trips' during this era ...<|separator|>
  52. [52]
    Controlled Substance Act - StatPearls - NCBI Bookshelf - NIH
    This schedule includes diacetylmorphine (heroin), psychedelic drugs such as psilocybin, MDMA, lysergic acid diethylamide (LSD), and marijuana.[10] The most ...
  53. [53]
    Drug Scheduling - DEA.gov
    Some examples of Schedule I drugs are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone ...Missing: psilocybin | Show results with:psilocybin
  54. [54]
    Charles Manson: How the notorious cult leader brought an abrupt ...
    Nov 20, 2017 · It would be wrong in any way to underplay the calculation and the savagery involved in the murder of Sharon Tate and six other people in the ...Missing: prohibition | Show results with:prohibition
  55. [55]
    [PDF] The United States Print Media and its War on Psychedelic Research ...
    May 2, 2019 · Little has been written by historians regarding the media's portrayal of psychedelics in the 1960s and how it agreed with the government despite ...Missing: freakouts 1970s
  56. [56]
    The Rise of 1960s Counterculture and Derailment of Psychedelic ...
    Aug 9, 2024 · In the 1960s, the psychedelic music scene exploded, with bands like The Beatles, Jimi Hendrix and Jefferson Airplane, bringing psychedelics ...
  57. [57]
    The Abuse Potential of Medical Psilocybin According to the 8 ...
    Research and licit clinical use of LSD and psilocybin greatly slowed in the 1960s as amendments in 1962 and 1965 to the 1938 US Food Drug and Cosmetic Act ...
  58. [58]
    Psychedelic drug abuse potential assessment research for new drug ...
    Nov 1, 2022 · New medicines containing classic hallucinogenic and entactogenic psychedelic substance are under development for various psychiatric and neurological disorders.Psychedelic Drug Abuse... · 1. Introduction · 2. The Us Controlled...
  59. [59]
    [PDF] CONVENTION ON PSYCHOTROPIC SUBSTANCES, 1971
    The Convention on Psychotropic Substances, 1971, was adopted by a UN conference in Vienna, and opened for signature. States were invited to apply its measures ...
  60. [60]
    Convention on Psychotropic Substances 1971 - Unodc
    The Convention establishes an international control system for psychotropic substances. It responded to the diversification and expansion of the spectrum of ...
  61. [61]
    Exploring the subjective experience of rave party participants in ...
    Dec 6, 2023 · A distinctive feature of RMP is the wide-spread consumption of classic psychedelic/hallucinogens drugs (“mind-altering”) [6], including ...
  62. [62]
    Rave's Psychedelic Resurgence · Feature RA - Resident Advisor
    Jan 31, 2022 · We explore the renewed interest in LSD and psilocybin, their long history in the dance music scene and usage as tools for transformation—and fun ...
  63. [63]
    The Evolution Of Psychedelics At Dead Shows, Burning Man And ...
    Aug 29, 2023 · Test your drugs. “No drug use is 100% safe, this includes psychedelics,” shares DanceSafe founder Emanuel Sferios. “But knowing what drug you're ...Missing: history | Show results with:history
  64. [64]
    Why was early therapeutic research on psychedelic drugs ...
    Oct 21, 2021 · The demise of psychedelic drug research was not solely due to the 'War on Drugs'. It was hastened by tighter regulation of pharmaceutical research.
  65. [65]
    [PDF] EXPLAINING THE CRIMINALIZATION OF PSYCHEDELIC DRUGS
    psychedelic-induced psychosis in the 1960s were merely having “bad trips,” (see glossary) and experienced no lasting negative effects once the drug wore off ( ...
  66. [66]
    Psychedelic Rock: The History and Sound of Psychedelic Rock - 2025
    Jun 7, 2021 · 4 Characteristics of Psychedelic Rock ; 1. Sound effects ; 2. Inventive use of instruments ; 3. Improvisation ; 4. Abstract lyrics ...
  67. [67]
    Psychedelic Rock - SoundBridge
    Jan 17, 2024 · Characteristics of Psychedelic Rock. Psychedelic rock frequently incorporates hypnotic studio effects such as reverb, phasing, distortion, and ...
  68. [68]
    On This Day in 1967, The Beatles Made Psychedelic Rock ...
    May 26, 2025 · However, when it comes to cultural influence and trend-setting, Sgt. Pepper's Lonely Hearts Club Band is arguably the most revolutionary.
  69. [69]
    Syd Barrett: How LSD Created and Destroyed His Career With Pink ...
    Sep 8, 2020 · An over-reliance on psychedelic drugs drove the rock star from the bounds of reality and forced his bandmates to cut ties to keep their musical dreams alive.
  70. [70]
    Pink Floyd's trippy debut 'The Piper at the Gates of Dawn'
    Aug 5, 2021 · Pink Floyd's debut is a brilliant psychedelic journey through space and time, matched by an appropriate level of production that augmented the unhinged acid- ...
  71. [71]
    Acid Rock Music Guide: 4 Characteristics of Acid Rock - MasterClass
    Jun 7, 2021 · Acid rock is a subgenre of rock 'n' roll music that took hold in the psychedelic era of the late 1960s and early 1970s. The music took its name ...Missing: features | Show results with:features
  72. [72]
    Defining Acid Rock - It's Psychedelic Baby Magazine
    Jun 9, 2020 · Acid rock, then, is a heavy type of rock music with psychedelic influences. Musicians of this genre create sonic textures that culminate in a psychedelic ...
  73. [73]
    Freak-Folk Music: 4 Notable Freak-Folk Acts - 2025 - MasterClass
    Oct 26, 2021 · Freak folk draws on the music of folk musicians from the psychedelic era for new, unique hybrids of folk and rock.Missing: connection | Show results with:connection
  74. [74]
    Origins and Characteristics of Psychedelic Rock | Music History
    Drug-induced states sometimes resulted in unconventional instrument techniques; Extended jam sessions and improvisations became hallmarks of live performances ...
  75. [75]
    The History of Trance Music: From Goa to Global Festivals
    Feb 25, 2025 · Originating from psychedelic roots in Goa, trance has evolved into one of the most influential and widely loved EDM genres. Over the past three ...
  76. [76]
    Updating the dynamic framework of thought: Creativity and ...
    One early study found that indirect semantic priming was increased during the psychedelic state, which was interpreted to suggest that psychedelics may enable a ...2. Reconceptualizing... · 3. Incorporating The... · Appendix A. Supplementary...
  77. [77]
    Your Guides To Realising Your Purpose On The Planet: The Black ...
    Jun 21, 2017 · Probably the most common criticism levelled at psychedelic music is that it's pure escapism, with nothing to say. While it's difficult to ...
  78. [78]
    [PDF] Psilocybin, LSD, Mescaline and Drug-Induced Synesthesia
    Reported visual disturbances include experiences of external objects having an unusual variety of colors, textures and shapes and undergoing swift changes.Missing: distortions | Show results with:distortions
  79. [79]
    Broadband Cortical Desynchronization Underlies the Human ... - NIH
    We observed a broadband desynchronization of cortical oscillatory rhythms after psilocybin infusion and decreased brain network integrity.
  80. [80]
    https://www.classicposters.com/artist/wes-wilson/
  81. [81]
    An Exploration of the Psychedelic Aesthetic in Art - Art in Context
    Jun 2, 2021 · German American artist Peter Max was closely associated with both the Psychedelic Art and Pop Art movement during the 1960s and is regarded as a ...
  82. [82]
    CREAM - 1967 - DISRAELI GEARS - ALBUM ART PRINT - CLAPTON
    The front cover consists of a psychedelic collage with the title centred and band name below, surrounded by a floral arrangement.
  83. [83]
    Deliberately Disorienting | Cooper Hewitt, Smithsonian Design ...
    Oct 23, 2018 · A pioneering example of psychedelic design, this work was one of the 56 posters that Wes Wilson produced between 1966 and 1968 for the Fillmore Auditorium in ...
  84. [84]
    Psychedelic Patriotism: Peter Max Sparks a Debate on Modern ...
    Max had adopted psychedelic elements in his work by 1965 and had driven the popularity of psychedelic art for advertising and political purposes, designing a ...Missing: key | Show results with:key
  85. [85]
    The Psychedelic Poster Art of Wes Wilson, by Colin Brignall
    Designed for the Bill Graham Presents company for a gig in San Francisco's Fillmore Auditorium featuring bands Grateful Dead, The Canned Heat Blues Band and ...
  86. [86]
    [PDF] ALDOUS HUXLEY'S ISLAND REVISITED: PSYCHEDELICS AND ...
    Aldous Huxley's Island exemplifies radical agnosticism (among other things) through a pluralistic approach to psychedelics. Pala's psychoactive toadstool, ...
  87. [87]
    Island: Aldous Huxley's Psychedelic Utopia - jstor
    psychedelics cleansed the doors of his perception. That Huxley responded to these drugs as he did surely results in large part from the fact that they provided ...Missing: themes | Show results with:themes
  88. [88]
    [PDF] The Psychedelic Experience.Pdf - Leathersmithe
    THE PSYCHEDELIC EXPERIENCE. A manual based on THE TIBETAN BOOK OF THE DEAD, by Timothy Leary, Ralph Metzner & Richard Alpert. Page 2. General Introduction.
  89. [89]
    The Psychedelic Experience A Manual Based On The Tibetan Book ...
    May 26, 2018 · In this wholly unique book, the authors provide an interpretation of an ancient sacred manuscript, The Tibetan Book of the Dead, from a ...
  90. [90]
    Self unbound: ego dissolution in psychedelic experience - PMC
    Users of psychedelic drugs often report that their sense of being a self or 'I' distinct from the rest of the world has diminished or altogether dissolved.
  91. [91]
    Psychedelics alter metaphysical beliefs - PMC - NIH
    Psychedelics have been found to acutely increase psychological suggestibility, likely by relaxing the confidence of held beliefs thereby allowing for an easier ...
  92. [92]
    (PDF) Psychedelics alter metaphysical beliefs - ResearchGate
    Aug 6, 2025 · Together, these findings imply that psychedelic-use may causally influence metaphysical beliefs—shifting them away from 'hard materialism'. We ...
  93. [93]
    [PDF] Comforting delusions How to evaluate the plausibility of mystical ...
    Aug 14, 2024 · Psychedelics can cause mystical beliefs, like a loving consciousness, but these are criticized as delusional. Metaphysical agnosticism is ...Missing: expanded | Show results with:expanded
  94. [94]
    The making and breaking of the counter culture - Philosophy for Life
    Feb 28, 2019 · A second issue, one identified very well by Roszak, was that the counter culture fetishized psychedelics as the only route to enlightenment.
  95. [95]
    Psychedelic literary studies and the poetics of disruption - PMC - NIH
    Jun 9, 2023 · The most successful literary and artistic renderings of psychedelic states work not by providing reductive testimonies, but rather by disrupting ...
  96. [96]
    Ego-Dissolution and Psychedelics: Validation of the Ego ... - Frontiers
    Aims: The experience of a compromised sense of 'self', termed ego-dissolution, is a key feature of the psychedelic experience and acute psychosis.
  97. [97]
    Neural Mechanisms and Psychology of Psychedelic Ego Dissolution
    Here, we review the cognitive and neuroimaging evidence for the effects of psychedelics: in particular, their influence on selfhood and subject-object ...
  98. [98]
    The Pharmacology of Lysergic Acid Diethylamide: A Review - PMC
    In 1967, a report gave evidence for LSD‐induced chromosomal damage [57] ... In humans, LSD increases serum growth hormone with a peak at 120 min. but ...
  99. [99]
    The remarkable reimagining of psilocybin - Taylor & Francis Online
    Nov 2, 2023 · In 1958, Sandoz chemist Albert Hofmann first isolated a pure crystalline substance from Psilocybe mexicana in his Basel laboratory, giving it ...
  100. [100]
    Mescaline: The forgotten psychedelic - PubMed
    Jan 1, 2023 · Findings: Mescaline is a serotonin 5HT2A/2C receptor agonist, with its main hallucinogenic effects being mediated via its 5HT2A receptor agonist ...
  101. [101]
    Neuropharmacology of N,N-Dimethyltryptamine - PMC
    The hallucinogenic effects of DMT in the formulation of ayahuasca (0.6 - 0.85 mg/kg DMT; Riba et al., 2003) generally appear within 60 min, peak at 90 min ...
  102. [102]
    Neural correlates of the psychedelic state as determined by fMRI ...
    These results strongly imply that the subjective effects of psychedelic drugs are caused by decreased activity and connectivity in the brain's key connector ...
  103. [103]
    Exploring DMT: Endogenous role and therapeutic potential
    May 1, 2025 · These circumstances were termed endohuasca due to their endogenous origins and similarity to Ayahuasca's mechanism (Ujváry, 2014).
  104. [104]
    Classic and Nonclassic Targets in Psychedelic Drug Action - PMC
    In this mini-review, we will discuss how the 5-HT 2A receptor activation is just one facet of the complex mechanisms of action of serotonergic psychedelics.
  105. [105]
    The psychological processes of classic psychedelics in the ...
    May 5, 2022 · Neurobiological processes in psychedelic treatment. Exactly how classic psychedelics may work to reduce depression symptoms is still largely ...
  106. [106]
    Sustained effects of single doses of classical psychedelics in humans
    Jun 21, 2022 · A unique and compelling feature of psychedelics is that intake of just a single psychedelic dose is associated with long-lasting effects.
  107. [107]
    Comparative acute effects of mescaline, lysergic acid diethylamide ...
    May 25, 2023 · Autonomic effects of 500 mg mescaline, LSD, and psilocybin were moderate, with psilocybin causing a higher increase in diastolic blood pressure ...
  108. [108]
    Direct comparison of the acute effects of lysergic acid diethylamide ...
    Feb 25, 2022 · Psilocybin increased blood pressure more than LSD, whereas LSD increased heart rate more than psilocybin. However, both LSD and psilocybin ...<|separator|>
  109. [109]
    Adverse Events in Studies of Classic Psychedelics - PubMed
    Dec 1, 2024 · Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis ... Hallucinogens* / adverse effects; Humans ...
  110. [110]
    On Perception and Consciousness in HPPD: A Systematic Review
    Aug 10, 2021 · Sound prevalence rates are lacking, but the DSM-5 suggests that 4.2% of all hallucinogen users experience HPPD-like symptoms (American ...Introduction · Methods · Results · Discussion<|separator|>
  111. [111]
    Hallucinogen Persisting Perception Disorder: Etiology, Clinical ...
    Mar 16, 2018 · Hallucinogen Persisting Perception Disorder (HPPD) is a rare, and therefore, poorly understood condition linked to hallucinogenic drugs consumption.
  112. [112]
    Set and Setting: A Randomized Study of Different Musical Genres in ...
    ... empirically ... This study provides the first contemporary and within-subject experimental manipulation of session set and setting factors in psychedelic research ...
  113. [113]
    Harnessing Pharmacogenomics in Clinical Research on ... - NIH
    Sep 30, 2024 · In conclusion, considering early evidence that genetic factors can influence the effects of certain psychedelics, we suggest that ...
  114. [114]
    Our DNA Could Affect the Potency of Psychedelics in the Brain
    Jul 27, 2022 · A new study has identified that variation in genes coding for key receptors in our brains may alter the potency of psychedelic drugs.Missing: COMT | Show results with:COMT
  115. [115]
    [PDF] Humphry Osmond: The Psychedelic Psychiatrist - ARC Journals
    Treatment of Alcoholism: The Effects on Drinking Behaviour‟, Quarterly Journal of Studies of. Alcohol, 27, 469 – 82. 27 Osmond H. Dr. Osmond's Memos Heart ...
  116. [116]
    'Hitting Highs at Rock Bottom': LSD Treatment for Alcoholism, 1950 ...
    Initial experiments demonstrated unprecedented rates of abstinence among alcoholics treated with LSD. The approach gained support from the provincial government ...
  117. [117]
    psychiatric experimentation with LSD in historical perspective
    ... Abram Hoffer (in Saskatoon). These medical researchers were first drawn to LSD because of its ability to produce a "model psychosis." Their experiments with ...
  118. [118]
    Prairies, psychedelics and place: The dynamics of region in ...
    ... schizophrenia and alcoholism. While they were not alone in their desire to use “mind-manifesting” chemicals to stimulate research in psychiatry at this time ...
  119. [119]
    Dr. Leary's Concord Prison Experiment: A 34 Year Follow-Up Study
    The original study involved the administration of psilocybin-assisted group psychotherapy to 32 prisoners in an effort to reduce recidivism rates. This follow- ...Missing: concordance | Show results with:concordance
  120. [120]
    [PDF] PAHNKE'S "GOOD FRIDAY EXPERIMENT": A LONG-TERM ...
    According to Pahnke, the experiment determined that "the persons who received psilocybin experienced to a greater extent than did the controls the phenom- ena ...Missing: concordance | Show results with:concordance
  121. [121]
    Looking Back: A brief history of psychedelic psychiatry | BPS
    Sep 3, 2014 · Osmond conducted experiments on himself with LSD and concluded that the drug could produce profound changes in consciousness. Osmond and Hoffer ...
  122. [122]
    LSD before Leary. Sidney Cohen's critique of 1950s psychedelic ...
    LSD had arrived in the United States in 1949 and was originally perceived as a psychotomimetic capable of producing a model psychosis. But in the mid 1950s ...Missing: early clinical trials modeling
  123. [123]
    The SIG Beat: Psychedelic Medicine
    Mar 16, 2023 · Federal funding on psychedelics would remain dry for 50 years, until 2021 when Johns Hopkins University (Baltimore) was awarded a nearly $4 ...
  124. [124]
    Trip therapy: Could psychedelics become mainstream medicines?
    Jan 25, 2023 · But in 1970, after the Controlled Substances Act put hallucinogens in the Schedule I category, many of the early pioneers in the field ...
  125. [125]
    Psychedelics: Where we are now, why we got here, what we must do
    The law does not outright ban research on Schedule I substances but it includes restrictions and significant barriers and requirements that discourage ...<|separator|>
  126. [126]
    The Revival of Psychedelic Research - UHN Research
    Feb 11, 2021 · In 1970, the US passed the Controlled Substances Act, blacklisting psychedelics and effectively ending all research for the next three decades.
  127. [127]
    DMT: The Spirit Molecule: A Doctor's Revolutionary Research Into ...
    Aug 1, 2002 · Throughout the studies, Strassman monitored the effects of the drug on heart rate, pulse, hormone levels, and body temperature. For some ...
  128. [128]
    DMT: The Spirit Molecule with Dr Rick Strassman - YouTube
    Jul 12, 2019 · From 1990 to 1995 our guest conducted DEA-approved clinical research at the University of New Mexico in which he injected sixty volunteers ...
  129. [129]
    History and future of the Multidisciplinary Association for ... - PubMed
    MAPS was created as a non-profit psychedelic pharmaceutical company in response to the 1985 scheduling of 3,4-methylenedioxymethamphetamine (MDMA).
  130. [130]
    A History and Overview of Clinical MDMA Research
    Apr 5, 2017 · MAPS founder Rick Doblin, Ph.D., learned about MDMA in 1982 as an ... Studies, or MAPS—in 1986. MAPS began funding animal toxicity ...
  131. [131]
    Why abandoning psychedelic research in the 1970s was a blow to ...
    Oct 3, 2025 · Work on medical uses of mind-altering substances was sidelined for decades by the political backlash against drugs, a misstep that has ...
  132. [132]
    Restrictive drug laws censor science, researchers say - Reuters
    Jun 11, 2013 · "The laws have never been updated despite scientific advances and growing evidence that many of these drugs are relatively safe. And there ...<|control11|><|separator|>
  133. [133]
    Drugs prohibition is criminals' gain, neuroscience's loss
    Jul 22, 2013 · The global prohibition of psychoactive drugs has arguably caused more suffering than it could ever prevent. A recent UN report shows that it ...
  134. [134]
    Psilocybin produces substantial and sustained decreases in ... - NIH
    High-dose psilocybin produced large decreases in clinician- and self-rated measures of depressed mood and anxiety, along with increases in quality of life.
  135. [135]
    Five-year outcomes of psilocybin-assisted therapy for Major ...
    Sep 4, 2025 · Results. Significant and sustained reductions in depression were observed, with 67% in remission for at least five years post-treatment. Anxiety ...
  136. [136]
    FDA Grants Breakthrough Therapy Designation for MDMA-Assisted ...
    Aug 26, 2017 · The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to MDMA for the treatment of posttraumatic stress disorder (PTSD).
  137. [137]
    COMPASS Pathways receives FDA Breakthrough Therapy ...
    Oct 23, 2018 · COMPASS Pathways is now running the first large-scale psilocybin therapy clinical trial for treatment-resistant depression, which will take place in Europe and ...
  138. [138]
    FDA Grants Psilocybin Second Breakthrough Therapy Designation
    Nov 25, 2019 · The US Food and Drug Administration (FDA) has granted the Usona Institute breakthrough therapy designation for psilocybin for the treatment of major depressive ...
  139. [139]
    Psilocybin-assisted therapy for depression: A systematic review and ...
    The meta-analysis included 9 studies (pooled n = 596) and yielded a large effect size in favour of psilocybin (SMD = -0.78; p<0.001). Risk ratios for response ...
  140. [140]
    MDMA-assisted therapy for severe PTSD: a randomized, double ...
    May 10, 2021 · MDMA-assisted therapy for PTSD was granted an FDA Breakthrough Therapy designation, and the protocol and statistical analysis plan (SAP) ...
  141. [141]
    A single dose of LSD can treat anxiety and depression for months ...
    Sep 4, 2025 · A new study finds that a single dose of LSD can ease a person's anxiety for months. This could give legitimacy to research on a range of ...Missing: RCTs 2020-2025
  142. [142]
    Efficacy of psilocybin for treating symptoms of depression - The BMJ
    May 1, 2024 · In our meta-analysis we found that psilocybin use showed a significant benefit on change in depression scores compared with placebo. This is ...
  143. [143]
    https://www.sciencedirect.com/science/article/pii/S0278584625002957
  144. [144]
    On the Relationship between Classic Psychedelics and Suicidality
    Mar 11, 2021 · In recent psychedelic therapy clinical trials, we found no reports of increased suicidality and preliminary evidence for acute and sustained ...
  145. [145]
    Ethical and Practical Considerations for the Use of Psychedelics in ...
    Mar 29, 2023 · For MDMA, the most common adverse events are mild and transient and include muscle tightness, decreased appetite, nausea, hyperhidrosis, feeling ...
  146. [146]
    Risk of bias in randomized clinical trials on psychedelic medicine - NIH
    Jul 4, 2023 · (b) Many trials had small sample sizes, leaving them vulnerable to participant dropout. For example, we rated Davis et al. (2021) and Gasser ...Study Selection · Risk Of Bias · Discussion
  147. [147]
    Control Group Outcomes in Trials of Psilocybin, SSRIs, or ...
    Jul 30, 2025 · This meta-analysis found that participants receiving control treatment in psilocybin trials had significantly less improvement in depression ...
  148. [148]
    AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel ...
    Aug 25, 2025 · This transaction builds upon AbbVie and Gilgamesh's 2024 collaboration and option-to-license agreement to advance the development of next- ...
  149. [149]
    Psychedelics Space Enters New Era as AbbVie Dives In - BioSpace
    Sep 22, 2025 · With AbbVie's $1.2 billion acquisition of Gilgamesh Pharmaceuticals' lead depression drug, the psychedelic therapeutics space has soundly ...
  150. [150]
    2 STATES IN WEST BAN SALE OF LSD; California and Nevada Act ...
    Nevada and California today became the first states to enact controls over the hallucinogenic drug LSD.
  151. [151]
    The Buyers - A Social History Of America's Most Popular Drugs - PBS
    Soon a black market for LSD in the US emerged. In 1966 the Grunsky Bill was passed by Congress, which prohibited the possession, manufacturing, sale and ...<|separator|>
  152. [152]
    21 U.S. Code § 812 - Schedules of controlled substances
    The drug or other substance has a high potential for abuse. (B). The drug or other substance has no currently accepted medical use in treatment in the United ...Missing: LSD | Show results with:LSD
  153. [153]
    [PDF] Rise of Hallucinogen Use - Office of Justice Programs
    Many natu- rally occurring substances such as peyote, psilocybin, or mescaline have long been used in cultural and religious contexts, and LSD was synthesized ...
  154. [154]
    90th Congress (1967-1968): An Act to amend the Federal Food ...
    H.R. 14096 - An Act to amend the Federal Food, Drug, and Cosmetic Act to prescribe penalties for the possession of LSD and other hallucinogenic drugs by ...
  155. [155]
    Denver Votes To Decriminalize Possession Of Magic Mushrooms
    May 9, 2019 · Denver voters narrowly approved a grassroots ballot initiative to decriminalize psilocybin mushrooms, commonly referred to as psychedelic mushrooms.
  156. [156]
    Oregon Measure 109, Psilocybin Mushroom Services Program ...
    Oregon Measure 109, the Psilocybin Program Initiative was on the ballot in Oregon as an initiated state statute on November 3, 2020. It was approved.
  157. [157]
    Oregon Health Authority : Oregon Psilocybin Services
    Oregon Psilocybin Services (OPS) regulates psilocybin products and services, implementing Ballot Measure 109. Service centers began opening in summer 2023.
  158. [158]
    Psychedelics Legalization & Decriminalization Tracker
    Measure 110 was largely repealed in 2024. 2020. Measure 109, the Oregon Psilocybin Services Act, directs the Oregon Health Authority (OHA) to license and ...
  159. [159]
    Multidisciplinary Association for Psychedelic Studies – MAPS ...
    MAPS is a nonprofit organization that provides public resources and leadership as we work together to create legalresponsibleevidence–based pathways to ...Take Action · MDMA · Advancing Research · About MAPS
  160. [160]
    Psychedelic Research Institutes & Organizations - Third Wave
    A directory of the most notable research institutes and organizations that are working to advance psychedelic science and institutional reform.Missing: advocacy | Show results with:advocacy
  161. [161]
    https://zombiemyco.com/blogs/mushrooms/psychedelic-bills-2025-what-s-changing
  162. [162]
    Bill Text: NJ S2283 | 2024-2025 | Regular Session | Introduced
    2024 NJ S2283 (Text) "Psilocybin Behavioral Health Access and Services Act"; authorizes production and use of psilocybin to promote health and wellness.
  163. [163]
    Ethical principles of traditional Indigenous medicine to guide ... - NIH
    The resurgence of Western psychedelic research and practice has led to increasing concerns from many Indigenous Nations regarding cultural appropriation, ...
  164. [164]
    [PDF] An Equitable High: Indigenous People Must Have a Seat at the ...
    May 15, 2025 · This paper comprises three parts—the first section will address the history of psychedelic drugs, focusing on a discussion of the war on drugs.
  165. [165]
    FDA Rejects Lykos' MDMA-Assisted PTSD Therapy After Negative ...
    Aug 9, 2024 · The FDA late Friday rejected Lykos Therapeutics' New Drug Application for its midomafetamine (MDMA)-assisted therapy for post-traumatic stress disorder.
  166. [166]
    Psychedelics in 2025: What's Evidence-Based, | Medical Toxicology
    Sep 29, 2025 · As of September 2025, there is no FDA approval for psilocybin; Phase 3 data in TRD are emerging [1]. Did FDA reject MDMA-assisted therapy? Yes.
  167. [167]
    https://bynx.co/the-psychedelic-60s/
  168. [168]
    [PDF] Psychedelic Drugs and the Fine Arts in the 1960s and 1970s
    LSD was a significant drug that helps to characterize the fine arts aspect of pop culture in the 1960s and 1970s. The first primary source helps to support the ...Missing: sensationalism overdoses freakouts
  169. [169]
    From Egoism to Ecoism: Psychedelics Increase Nature Relatedness ...
    In this sense, modern research is demonstrating psychedelics can act as biophilia enhancing agents. 4.3. Ego-Dissolution Mediates Psychedelic-Induced Increases ...
  170. [170]
    Mystical experiences occasioned by the hallucinogen psilocybin ...
    Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. Katherine A. MacLean, Matthew W ...
  171. [171]
    Effects of psilocybin therapy on personality structure - PubMed Central
    Moreover, psilocybin and LSD may increase the NEO‐PI‐R 39 personality trait Openness to Experience (or simply 'Openness') in healthy volunteers after a single ...
  172. [172]
    The costs and benefits of psychedelics on cognition and mood
    Mar 1, 2023 · Anecdotal evidence has indicated that psychedelic substances may acutely enhance creative task performance, although empirical support for this claim is mixed ...
  173. [173]
    Feel connected to create: Self-reported psychedelic drug users ...
    We found that psychedelic drug users showed a higher sense of connectedness, higher creative potential (ie, originality, fluency), and more creative activities.
  174. [174]
    Psychedelic use linked to increased risk of schizophrenia, study finds
    Nov 13, 2024 · Hallucinogens include drugs such as psilocybin, LSD, DMT (Ayahuasca), and MDMA (Ecstasy). The study, which followed over 9.2 million individuals ...
  175. [175]
    Hallucinogens Tied to Striking Increased Risk of SSD - Medscape
    Nov 13, 2024 · ED visits related to hallucinogen use are linked to a 21-fold increased risk of schizophrenia spectrum disorder, results of a large ...<|separator|>
  176. [176]
    Adolescent Psychedelic Use and Psychotic or Manic Symptoms
    Mar 13, 2024 · Psychedelic use was significantly associated with more manic symptoms for individuals with a higher genetic vulnerability to schizophrenia or bipolar I ...
  177. [177]
    Reconsidering evidence for psychedelic-induced psychosis - Nature
    Nov 27, 2024 · Persons with schizophrenia are excluded from psychedelic-assisted therapy due to concerns about the risk of triggering or worsening ...
  178. [178]
    Reconsidering evidence for psychedelic-induced psychosis
    Persons with schizophrenia are excluded from psychedelic-assisted therapy due to concerns about the risk of triggering or worsening psychosis.
  179. [179]
    Why was early therapeutic research on psychedelic drugs ... - PubMed
    Oct 21, 2021 · The demise of psychedelic drug research was not solely due to the 'War on Drugs'. It was hastened by tighter regulation of pharmaceutical research.Missing: replications | Show results with:replications
  180. [180]
    Clinical Effects of Psychedelic Substances Reported to United ...
    Aug 1, 2024 · Overall, 27,444 (50.3%) psychedelic exposures had symptoms that required treatment, severe residual or prolonged symptoms, or death.
  181. [181]
    Commentary on Darke et al.: Expanded psychedelic access requires ...
    Jun 17, 2024 · As psychedelic use expands, the number of adverse effects will increase proportionally. New frameworks for monitoring safety outcomes on a population level are ...
  182. [182]
    Psychedelic crossings: American mental health and LSD in the 1970s
    Jun 23, 2019 · This article places a spotlight on LSD, psychedelic medicine and American mental health in the 1970s, an era in which researchers and practitioners continued ...Missing: sensationalism overdoses freakouts
  183. [183]
    How corporate involvement in psychedelic research could threaten ...
    Apr 22, 2024 · The influence of conflicts of interest on psychedelic studies can contribute to an overly optimistic opinion by researchers, the public and policymakers.
  184. [184]
    Psychedelics in PERIL: The Commercial Determinants of Health ...
    Our analysis suggests financial relationships with the corporate psychedelic sector may create varying degrees of risk to a research program's purpose, ...
  185. [185]
    The Birth of the Psychedelic Industry: Capitalising on the ...
    Dec 26, 2024 · The commercialisation of psychedelics risks overshadowing their original therapeutic potential, as the need for substantial capital ...
  186. [186]
    'Authentic' ayahuasca rituals sought by tourists often ignore ...
    Jun 28, 2024 · The psychotropic allure of the ayahuasca plant for hundreds of thousands of non-Indigenous consciousness seekers is raising many concerns.
  187. [187]
    Adverse effects of ayahuasca: Results from the Global ... - NIH
    Nov 16, 2022 · While there is a high rate of adverse physical effects and challenging psychological effects from using ayahuasca, they are not generally severe ...
  188. [188]
    Ethical Concerns about Psilocybin Intellectual Property - PMC - NIH
    Jan 1, 2021 · From an indigenous perspective, psilocybin research and drug development tells a story of extraction, cultural appropriation, bioprospecting, ...Missing: stripping | Show results with:stripping
  189. [189]
    Ethical Concerns about Psilocybin Intellectual Property
    Jan 1, 2021 · Six decades later, North-American and European businessmen disproportionately reap financial gain from psychedelics. In October 2020, one of the ...
  190. [190]
    How to fold Indigenous ethics into psychedelics studies - Science
    Feb 23, 2023 · Media buzz has generated a rush to legalize their therapeutic use, catapulting the global psychedelic drugs market from $3.8 billion in 2020 to ...
  191. [191]
    Indigenous Philosophies and the "Psychedelic Renaissance"
    Jul 30, 2022 · Mazatec shamans consume psychoactive mushrooms as part of their healing rituals to access MTH power inherent in the landscape, particularly the ...Language And Land · Land Back, Psychedelics, And... · Conclusion
  192. [192]
    [PDF] Socio-Demographic Diversity in Psychedelic Research
    An analysis of the ethnic breakdown of trial participants in 20 psychedelic-assisted psychotherapy studies from 2006 to 2023 revealed that almost 80% were non- ...
  193. [193]
    A systematic review of participant diversity in psychedelic-assisted ...
    Compared to their representation in the US population and non-psychedelic clinical trials, Black/African-American participants (2.2%) and Hispanic/Latino ...
  194. [194]
    Informed Consent to Psychedelic-Assisted Psychotherapy: Ethical ...
    Jan 17, 2024 · The unpredictability of the psychedelic experience may alter or impair an individual's ability to consent or express themselves authentically in ...
  195. [195]
    Essentials of Informed Consent to Psychedelic Medicine
    Apr 10, 2024 · Unique Challenges of Psychedelic Informed Consent. Psychedelics have unique properties that complicate the informed consent process (Table 1).
  196. [196]
    Could MDMA Help With PTSD, Depression and Anxiety ...
    Apr 14, 2019 · The article acknowledges the momentum of MAPS' psychedelic research in the United States as a catalyst to the recently announced psychedelic ...Missing: 2010 Griffiths
  197. [197]
    MAPS psychedelics research for MDMA therapy comes under scrutiny
    May 13, 2024 · Research on MDMA has shown it can be effective for PTSD, but approval of the treatment isn't yet guaranteed.Missing: 2010 catalysts Griffiths psilocybin<|separator|>
  198. [198]
    Evidence Brief: Psychedelic Medications for Mental Health ... - NCBI
    MDMA was the only psychedelic used in studies of adults with PTSD. Psilocybin and ayahuasca were used most often in studies of adults with depression or ...
  199. [199]
    Psychedelics in Clinical Trials: A Promising Frontier in Mental Health ...
    Jul 22, 2025 · With over 100 ongoing psilocybin clinical trials, there has been growing interest in the therapeutic potential of psychedelic drugs in recent ...Missing: surge | Show results with:surge
  200. [200]
    The emergence of psychedelics as medicine
    Jun 1, 2024 · Psilocybin, LSD and other psychedelic drugs were once considered promising treatments for depression, anxiety and other mental health ailments.Mdma · Psilocybin · The Role Of TherapyMissing: disruption empirical
  201. [201]
    Psychedelics and Neural Plasticity: Therapeutic Implications
    Nov 9, 2022 · Emerging evidence suggests that psychedelic drugs may exert some of their long-lasting therapeutic effects by inducing structural and functional neural ...Missing: 2024 | Show results with:2024
  202. [202]
    Effects of psychedelics on neurogenesis and broader neuroplasticity
    Dec 19, 2024 · This review presents an extensive study into how different psychedelics may affect the birth of new neurons and other brain-related processes.Missing: milestones | Show results with:milestones
  203. [203]
    Cannabis and hallucinogen use among adults remained at historic ...
    Aug 29, 2024 · Hallucinogen use in the past year continued a five-year steep incline for both adult groups, reaching 9% for adults 19 to 30 and 4% for adults ...
  204. [204]
    Magic Mushrooms Are Most-Used Psychedelic Drug - RAND
    Jun 27, 2024 · Psilocybin mushrooms are the most used psychedelic in the US, with 8 million adults using it in 2023. 12% of respondents have used it at some ...
  205. [205]
    Psychedelic-Assisted Psychotherapy After COVID-19 - NIH
    The legacy of mental health problems that will be left behind by COVID-19 incites innovative solutions to address rising rates of PTSD, depression, anxiety, ...
  206. [206]
    New study links psychedelic use to mental health recovery in times ...
    Aug 4, 2025 · Unlike other drug users, individuals who used psychedelics and cannabis during the pandemic saw average improvements in anxiety and ...
  207. [207]
    Associations between the use of psychedelics and other ... - Frontiers
    Jun 14, 2023 · Those who primarily used psychedelics and cannabis during the COVID-19 pandemic had worse mood self-assessment and resilience scores compared to those who ...
  208. [208]
    Psychedelic Drugs Market Size & Share Analysis - Mordor Intelligence
    Jun 10, 2025 · The psychedelic drugs market size is USD 4.08 billion in 2025 and is projected to expand to USD 7.75 billion in 2030, translating into a robust 13.69% CAGR for ...
  209. [209]
    Drug companies are investing big in psychedelics, but can they ...
    Mar 6, 2022 · The first US company to be rewarded for trying to legitimize a mind-altering drug was Johnson & Johnson's Janssen Pharmaceuticals, which in ...Missing: Otsuka MindMed
  210. [210]
    Otsuka Pharmaceutical to Acquire Mindset Pharma - Otsuka US
    Sep 1, 2023 · Otsuka Pharmaceutical to Acquire Mindset Pharma - Strengthens pipeline in the area of psychiatric and neurological disorders · Avanir business is ...Missing: investments J&J<|separator|>
  211. [211]
    A landscape analysis of psychedelic retreat organizations ...
    May 2, 2025 · One common pathway to accessing psychedelics is through psychedelic retreats. While individual retreats have been characterized in the ...
  212. [212]
    Psychedelic Retreats: A Growing Trend In Wellness - Zamnesia
    Jul 9, 2024 · Are psychedelics the final frontier of wellness? Quite possibly. Psychedelic retreats were once the preserve of a niche subculture, but now they ...Missing: apps | Show results with:apps
  213. [213]
    How Psychedelic Retreats Became a Corporate Group Activity
    Apr 14, 2025 · Business Trip: How Psychedelic Retreats Became the Hottest Corporate Group Activity. The key to these retreats is what is known as integration.Missing: apps | Show results with:apps
  214. [214]
    Study Details Misuse of Scientific Publications by Opioid Industry
    Oct 24, 2024 · Analysis finds key scientific articles were cited to support unsubstantiated industry claims in more than 3600 documents in the UCSF-JHU ...Missing: psychedelic unevidenced parallels
  215. [215]
    Psychedelic Commercialization: A Wide-Spanning Overview of the ...
    Psychedelic drug development is fraught with a number of regulatory and financial hurdles. Primary among these is the status of many psychedelics as Schedule I ...